Eterna Operating Cycle from 2010 to 2026
| ERNA Stock | USD 1.24 0.02 1.64% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 246.66 | Current Value 363.74 | Quarterly Volatility 950.58382964 |
Check Eterna Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eterna Therapeutics' main balance sheet or income statement drivers, such as Total Revenue of 497.6 K, Gross Profit of 415.5 K or Other Operating Expenses of 32.9 M, as well as many indicators such as Price To Sales Ratio of 270, Dividend Yield of 1.0E-4 or PTB Ratio of 58.81. Eterna financial statements analysis is a perfect complement when working with Eterna Therapeutics Valuation or Volatility modules.
Eterna | Operating Cycle | Build AI portfolio with Eterna Stock |
Analyzing Eterna Therapeutics's Operating Cycle over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Operating Cycle has evolved provides context for assessing Eterna Therapeutics's current valuation and future prospects.
Latest Eterna Therapeutics' Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of Eterna Therapeutics over the last few years. It is Eterna Therapeutics' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eterna Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
Eterna Operating Cycle Regression Statistics
| Arithmetic Mean | 629.72 | |
| Geometric Mean | 134.81 | |
| Coefficient Of Variation | 150.95 | |
| Mean Deviation | 777.19 | |
| Median | 149.74 | |
| Standard Deviation | 950.58 | |
| Sample Variance | 903,610 | |
| Range | 2.3K | |
| R-Value | 0.49 | |
| Mean Square Error | 736,790 | |
| R-Squared | 0.24 | |
| Significance | 0.05 | |
| Slope | 91.37 | |
| Total Sum of Squares | 14.5M |
Eterna Operating Cycle History
About Eterna Therapeutics Financial Statements
Eterna Therapeutics stakeholders use historical fundamental indicators, such as Eterna Therapeutics' Operating Cycle, to determine how well the company is positioned to perform in the future. Although Eterna Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Eterna Therapeutics' assets and liabilities are reflected in the revenues and expenses on Eterna Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Eterna Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 246.66 | 363.74 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Eterna Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eterna Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eterna Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eterna Therapeutics Stock:Check out the analysis of Eterna Therapeutics Correlation against competitors. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. Projected growth potential of Eterna fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Eterna Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Eterna Therapeutics requires distinguishing between market price and book value, where the latter reflects Eterna's accounting equity. The concept of intrinsic value—what Eterna Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Eterna Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Eterna Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Eterna Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Eterna Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.